BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 7, Issue 12
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (8885)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Tables (1-8) series.
Item 
Count 
PDF557
WORD301
HTML3569
Tables (1-8)578
 Sum=5005
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1495
Download2388
 Sum=3883
Jun 28, 2015 (publication date) through Mar 21, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 28, 2015; 7(12): 1606-1616
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1606
Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?
Chrysoula Pipili, Evangelos Cholongitas
Chrysoula Pipili, Division of Nephrology, Royal Infirmary of Edinburgh, Scotland EH16 4SA, United Kingdom
Evangelos Cholongitas, 4th Department of Internal Medicine, Medical, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece
Author contributions: Pipili C and Cholongitas E contributed equally in writing and editing of the article.
Conflict-of-interest: None.
Correspondence to: Evangelos Cholongitas, Assistant Professor of Internal Medicine, 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 49, Konstantinopoleos Street, 54642 Thessaloniki, Greece. cholongitas@yahoo.gr
Telephone: +30-23-10892110 Fax: +30-23-10992940
Received: December 13, 2014
Peer-review started: December 13, 2014
First decision: January 8, 2015
Revised: May 18, 2015
Accepted: June 1, 2015
Article in press: June 2, 2015
Published online: June 28, 2015
Processing time: 198 Days and 1.8 Hours
Core Tip

Core tip: Treatment landscape for liver transplant (LT) candidates and recipients with chronic hepatitis C is rapidly shifting due to novel updated data on direct antiviral agents (DAAs); Patients with decompensated cirrhosis awaiting LT should be treated with the interferon (IFN)-free, new generation DAAs, with or without ribavirin (RBV) regimens; IFN-free combinations of sofosbuvir with other novel DAAs with or without RBV led to remarkable on-treatment virological response along with minimal adverse effects “on difficult to treat” LT recipients with recurrent hepatitis C - those with chronic hepatitis C genotype 1, decompensated cirrhosis with Child-Pugh stage B and C as well as previously intolerant or non responsive to IFN therapy; Evidence regarding the efficacy and safety of novel combinative treatments although are very promising, refer still to patients case series.
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345